🔗 Share this article

Given that the United States proceeds with sweeping revisions to its vaccine schedules, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who rose to prominence by expressing skepticism about Covid shots in the pandemic and has zeroed in on possible deaths following COVID-19 vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Vaccine Program

Health officials were set to announce sweeping revisions to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s vaccine program, sources say – a substantial departure that would put the US out of alignment with much of the world with insufficient data for improved outcomes. The planned update has been delayed until the coming year.

Instead of the director of the vaccine center, Høeg is set to address the audience at the meeting. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the office this year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a tighter collaboration between the pharmaceutical and biologics divisions as Høeg and Prasad strengthen their influence at the agency – and it points to a greater focus upon dismantling already-approved immunizations at the FDA.

Høeg has repeatedly called for halting some childhood shot schedules in the US in order to be more like Denmark, a society with nationalized medicine and a citizenry roughly the population of the state of Wisconsin.

So far statements, she has persisted in emphasizing on immunizations – typically the purview of Prasad, head of the FDA’s CBER – rather than drug regulation.

Doubts Over Expertise

The appointee has no obvious track record in drug development, approval processes or management, which has been standard for previous heads of the CBER. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for leading the CDER, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in managing a large organization. She is not an expert in pharmaceutical oversight.”

Former commissioners of the center would “grasp laws and regulations and the science of medication creation”, said a former acting FDA commissioner. “Frankly, she lacks the type of experience that former directors who headed CBER have had.”

The drug center has an enormous workload at the FDA, the former commissioner pointed out.

“Everybody just zeroes in on the new drug program, but the generic drug division authorizes a multitude of generic drugs. There’s a biologic copycat branch, over-the-counter program and more, and each of these must be supervised,” Woodcock explained. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

There is also, a significant leadership element to the position, which oversees more than 5,000 staff members. “It’s a massive leadership role, if you execute it properly,” Woodcock said.

Official Statement and Contentious Programs

When asked about inquiries about Dr. Høeg's fitness for the role and whether this appointment represents more teamwork among agency officials on vaccines, a press secretary responded that the “inquiries are based on flawed presumptions”.

“Her experience is consistent with the duties of her position,” the representative explained, noting the time Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the commissioner’s controversial expedited review system, a contentious expedited medication authorization process that reportedly troubled her preceding directors. “By what process are these therapies being chosen for this fast-track system? Who makes the choices?” Dr. Howard questioned. “There is a lot of lack of transparency happening at the FDA right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards more relaxed regulations of pharmaceuticals, with the exception of shots.”

Documented History on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if concerning, history, critics observe. She authored a analysis using unverified crowd-sourced reports to estimate the rate of heart inflammation following Covid immunization. She advised the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to imply Covid vaccines are riskier than they are.

Among her “wish list” for the incoming federal leadership included changing rules for recently developed shots and discontinuing “non-essential” immunizations, she stated post-election on a online show. At the FDA, Høeg has according to sources proposed barring adolescent males from obtaining Covid vaccinations.

“She’s an all-around true believer who commences with her beliefs and reverse-engineers to retrofit the data in a extremely disingenuous, dishonest way,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with fellow contrarians, {like|